CIK 0001674416
- Large accelerated filer
CRISPR Therapeutics AG
Sign in to watch- Ticker
- CRSP
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- Switzerland
- Entity type
- Operating
- EIN
- 473173478
- Phone
- +1 617-315-4600
- Business address
- BAARERSTRASSE 14, ZUG, Switzerland
- Former names
- CRISPR Therapeutics AG
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,881,673
- in 7 filings, $1.5M under 10b5-1 plans
Net −$4,881,673. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2017-05-05 | Novak Rodger Chief Executive Officer | Sale | −616 | $16.92 | $10K | 1,215,005 |
| 2017-05-05 | Novak Rodger Chief Executive Officer | Exercise or conversion · Stock Options (Right to Buy) | −616 | 168,093 | ||
| 2017-05-04 | Novak Rodger Chief Executive Officer | Exercise or conversion | +13,191 | $1.81 | $24K | 1,229,196 |
| 2017-05-04 | Novak Rodger Chief Executive Officer | Sale | −13,191 | $16.37 | $216K | 1,215,005 |
| 2017-05-04 | Novak Rodger Chief Executive Officer | Exercise or conversion · Stock Options (Right to Buy) | −13,191 | 168,709 | ||
| 2017-05-03 | Kulkarni Samarth Please See Remarks | Grant or award · Stock Options (Right to Buy) | +100,000 | 100,000 | ||
| 2017-05-03 | Novak Rodger Chief Executive Officer | Exercise or conversion | +20,269 | $1.81 | $37K | 1,235,274 |
| 2017-05-03 | Novak Rodger Chief Executive Officer | Sale | −19,247 | $16.05 | $309K | 1,216,027 |
| 2017-05-03 | Novak Rodger Chief Executive Officer | Sale | −1,022 | $16.64 | $17K | 1,215,005 |
| 2017-05-03 | Novak Rodger Chief Executive Officer | Exercise or conversion · Stock Options (Right to Buy) | −20,269 | 181,900 | ||
| 2017-05-02 | Novak Rodger Chief Executive Officer | Exercise or conversion | +15,924 | $1.81 | $29K | 1,230,929 |
| 2017-05-02 | Novak Rodger Chief Executive Officer | Sale | −15,924 | $16.53 | $263K | 1,215,005 |
| 2017-05-02 | Novak Rodger Chief Executive Officer | Exercise or conversion · Stock Options (Right to Buy) | −50,000 | 202,169 | ||
| 2017-05-01 | Dylan-Hyde Tyler Chief Legal Officer | Sale | −1,852 | $16.61 | $31K | 168,204 |
| 2017-04-28 | Dylan-Hyde Tyler Chief Legal Officer | Sale | −4,912 | $16.62 | $82K | 170,056 |
| 2017-04-27 | Kulkarni Samarth Chief Business Officer | Exercise or conversion | +2,206 | $1.81 | $4K | 136,253 |
| 2017-04-27 | Kulkarni Samarth Chief Business Officer | Sale | −2,206 | $16.78 | $37K | 134,047 |
| 2017-04-27 | Kulkarni Samarth Chief Business Officer | Exercise or conversion · Stock Options (Right to Buy) | −2,206 | 294,558 | ||
| 2017-04-27 | Dylan-Hyde Tyler Chief Legal Officer | Sale | −13,527 | $16.84 | $228K | 174,968 |
| 2017-04-26 | Kulkarni Samarth Chief Business Officer | Exercise or conversion | +3,275 | $1.81 | $6K | 137,322 |
Page 65 of 74 · 1,471 trades